The Truth of the Matter: An Evidence-Based Review of the Newer Antihyperglycemic Agents for T2DM: A hot° seat™ Program

Saturday, April 2, 2016 | 6:30 – 9:00 PM EST
Renaissance Boston Waterfront Hotel, Pacific Ballroom

This course is a live CME-certified ancillary symposium presented at ENDO 2016, the Endocrine Society's 98th Annual Meeting and Expo, held in Boston, Massachusetts, April 1–4, 2016. ENDO 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2016 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2016 to attend an ENDO 2016 ancillary symposium.

This activity is supported by an educational grant from AstraZeneca.


Opening and Welcome
Program Director: Vivian Fonseca, MD – Tulane University

Current Treatment Recommendations in T2DM
Zachary Bloomgarden, MD – Mount Sinai School of Medicine

Effects of Newer Antihyperglycemic Agents on Glycemic Control and Body Weight
Derek LeRoith, MD, PhD – Icahn School of Medicine at Mount Sinai

Using Insulin in Combination with Newer Agents
James Gavin, MD – Emory Unviersity

Cardiovascular Outcomes Trials and Newer Antihyerglycemic Agents - What We Know Now
Derek LeRoith, MD, PhD – Icahn School of Medicine at Mount Sinai

Interpretation of Additional Recent Safety Information for Newer Antihyerglycemic Agents
Zachary Bloomgarden, MD – Mount Sinai School of Medicine

Special Populations and Newer Agents in T2DM
James Gavin, MD – Emory Unviersity

Panel Discussion and Audience Questions

Target Audience

This activity is intended for endocrinologists, internists, surgeons, basic scientists, and other health care professionals with a shared special interest in the latest advances in hormone research and clinical endocrinology.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Review recent data on using agents within newer treatment classes (ie, DPP-4 inhibitors, GLP-1 RAs, and SGLT2 inhibitors), in complementary combinations with other antihyperglycemic agents and with insulin
  • Summarize current evidence pertaining to the effects of newer agents on cardiovascular events and cardiovascular mortality
  • Identify relevant patient characteristics influencing the selection of newer antihyperglycemic agents

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Boston, MA 02210
United States

Vivian Fonseca, MD – Program Director
Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, Louisiana

Zachary Bloomgarden, MD
Clinical Professor
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Derek LeRoith, MD, PhD
Professor of Medicine
Dvision of Endocrinology, Diabetes and Bone Disease
Icahn School of Medicine at Mount Sinai
New York, New York

James Gavin, MD
Chief Medical Officer and Chief Executive Officer
Healing Our Village
Clinical Professor of Medicine
Emory University
Atlanta, Georgia


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
James Gavin, MD: Advisor, Abbott Diabetes Care, Boehringer Ingelheim, Intarcia Therapeutics, Vivus Pharmaceuticals, Inc.; Consultant, sanofi US; Consultant and Speaker, AstraZeneca Pharmaceuticals LP, Janssen Pharmaceuticals, Inc.; Speaker, Lilly-Boehringer Ingelheim Diabetes Alliance
Zachary Bloomgarden, MD: Consultant, Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb/AstraZeneca; Consultant and Speaker, Johnson & Johnson Services, Inc., Novo Nordisk A/S; Consultant and Stockholder Earnings from Novartis AG; Speaker, Merck & Co., Santarus, Inc.; Stockholder Earnings from Abbott, Covidien, Hospira, Pfizer Inc., F. Hoffman La-Roche Ltd, St. Jude Medical, Inc., Zoetis

The following faculty reported no relevant financial relationship(s): Vivian Fonseca, MD; Derek LeRoith, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi

The following SPC Committee members reported relevant financial relationships:
Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
E Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck
Lisa Nachtigall, MD: Consultant, Genentech; Consultant and Principal Investigator, Ipsen
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Guillermo E Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

The following SPC members reported no relevant financial relationships: John Carmichael, MD; Natalie Cusano, MD; Alan Kelly, MD; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society and IMNE staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation